144 related articles for article (PubMed ID: 16509584)
1. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors.
Deng J; Sanchez T; Neamati N; Briggs JM
J Med Chem; 2006 Mar; 49(5):1684-92. PubMed ID: 16509584
[TBL] [Abstract][Full Text] [Related]
2. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors.
Deng J; Lee KW; Sanchez T; Cui M; Neamati N; Briggs JM
J Med Chem; 2005 Mar; 48(5):1496-505. PubMed ID: 15743192
[TBL] [Abstract][Full Text] [Related]
3. Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
Hong H; Neamati N; Wang S; Nicklaus MC; Mazumder A; Zhao H; Burke TR; Pommier Y; Milne GW
J Med Chem; 1997 Mar; 40(6):930-6. PubMed ID: 9083481
[TBL] [Abstract][Full Text] [Related]
4. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.
Dayam R; Sanchez T; Neamati N
J Med Chem; 2005 Dec; 48(25):8009-15. PubMed ID: 16335925
[TBL] [Abstract][Full Text] [Related]
5. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
Deng J; Sanchez T; Al-Mawsawi LQ; Dayam R; Yunes RA; Garofalo A; Bolger MB; Neamati N
Bioorg Med Chem; 2007 Jul; 15(14):4985-5002. PubMed ID: 17502148
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching.
Nicklaus MC; Neamati N; Hong H; Mazumder A; Sunder S; Chen J; Milne GW; Pommier Y
J Med Chem; 1997 Mar; 40(6):920-9. PubMed ID: 9083480
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75.
De Luca L; Barreca ML; Ferro S; Christ F; Iraci N; Gitto R; Monforte AM; Debyser Z; Chimirri A
ChemMedChem; 2009 Aug; 4(8):1311-6. PubMed ID: 19565598
[TBL] [Abstract][Full Text] [Related]
8. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
9. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
10. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Clement O; Shoemaker R; Sei S; Neamati N
J Med Chem; 2005 Jan; 48(1):111-20. PubMed ID: 15634005
[TBL] [Abstract][Full Text] [Related]
11. Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase.
Barreca ML; De Luca L; Iraci N; Chimirri A
J Med Chem; 2006 Jun; 49(13):3994-7. PubMed ID: 16789757
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.
Barreca ML; Ferro S; Rao A; De Luca L; Zappalà M; Monforte AM; Debyser Z; Witvrouw M; Chimirri A
J Med Chem; 2005 Nov; 48(22):7084-8. PubMed ID: 16250669
[TBL] [Abstract][Full Text] [Related]
13. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
14. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
15. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors.
Mustata GI; Brigo A; Briggs JM
Bioorg Med Chem Lett; 2004 Mar; 14(6):1447-54. PubMed ID: 15006380
[TBL] [Abstract][Full Text] [Related]
17. Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase.
Yi J; Asante-Appiah E; Skalka AM
Biochemistry; 1999 Jun; 38(26):8458-68. PubMed ID: 10387092
[TBL] [Abstract][Full Text] [Related]
18. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
19. Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.
Walker MA; Johnson T; Ma Z; Banville J; Remillard R; Kim O; Zhang Y; Staab A; Wong H; Torri A; Samanta H; Lin Z; Deminie C; Terry B; Krystal M; Meanwell N
Bioorg Med Chem Lett; 2006 Jun; 16(11):2920-4. PubMed ID: 16546383
[TBL] [Abstract][Full Text] [Related]
20. Treating chemical diversity in QSAR analysis: modeling diverse HIV-1 integrase inhibitors using 4D fingerprints.
Iyer M; Hopfinger AJ
J Chem Inf Model; 2007; 47(5):1945-60. PubMed ID: 17661457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
